Skip to main content

Select Drug Profiles

Original Research

Diabetes Medications and Cancer Risk: Review of the Literature

Lindsay Sanders, DO, MPH, Anu P. Michael, MD, Scott R. Anderson, MS IV, Loida D. Nguyen, PharmD, BCPS, Zackary A. Johnson, MS II, Quang T. Nguyen, DO, FACE, FTOS

Stakeholder Perspective

Cancer Risk Associated with Antidiabetes Medications: Implications for Patients, Providers, and Payers

by Matthew Mitchell, PharmD, MBA, FAMCP

Cancer: Exploding Treatment and Diagnostic Pipeline, and Ever-Increasing Costs

Craig K. Deligdish, MD

Cardiometabolic Health

Value of Remote Disease Management of Arrhythmia Highlighted at ACC 2012

Cardiometabolic Health

Faster, Safer Discharge from Emergency Department with Coronary CT Angiography

Cardiometabolic Health

Levels of Gene Expression a New Noninvasive Way to Identify Obstructive CAD

Cardiometabolic Health

Vorapaxar, a Novel Antithrombotic Agent, Reduces Events but Increases Bleeding

Cardiometabolic Health

Triple-Antiplatelet Therapy Equal to Double-Dose Dual Therapy After Percutaneous Coronary Intervention

Value-Based Care in Cardiometabolic Health: A Medical Director’s Perspective on the Inaugural Edition

Gary M. Owens, MD

Cardiometabolic Health

Single-Agent Oral Regimen as Effective as Current Standard for Pulmonary Embolism, Less Bleeding

Cardiometabolic Health

Comparative Effectiveness Analysis of Coronary Bypass Surgery and Percutaneous Revascularization

Page 202 of 244
Results 2011 - 2020 of 2438